Join us at
February 26-28, 2019 | Hilton Tokyo Bay Hotel |Tokyo, Japan
Dan Zhang, PhD
Co-Founder & CEO Fountain Medical Development
an illustration of combined regulatory and clinical development strategies for peptides among ICH countries by taking advantage of new ICH guidelines such as E17 MRCT guideline. It will also compare the regulatory environment for oligonucleotides in the US and China.